Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Simona Soverini; Caterina De Benedittis; Cristina Papayannidis; Stefania Paolini; Claudia Venturi; Ilaria Iacobucci; Mario Luppi; Paola Bresciani; Marzia Salvucci; Domenico Russo; Simona Sica; Ester Orlandi; Tamara Intermesoli; Antonella Gozzini; Massimiliano Bonifacio; Gian Matteo Rigolin; Fabrizio Pane; Michele Baccarani; Michele Cavo; Giovanni Martinelli

doi:10.1002/cncr.28522

Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Simona Soverini, Caterina De Benedittis, Cristina Papayannidis, Stefania Paolini, Claudia Venturi, Ilaria Iacobucci, Mario Luppi, Paola Bresciani, Marzia Salvucci, Domenico Russo, Simona Sica, Ester Orlandi, Tamara Intermesoli, Antonella Gozzini, Massimiliano Bonifacio, Gian Matteo Rigolin, Fabrizio Pane, Michele Baccarani, Michele Cavo, Giovanni Martinelli

Risultato della ricerca: Contributo in rivista › Articolo in rivista

78 Citazioni (Scopus)

Abstract

Patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib with acquisition of BCR-ABL kinase domain (KD) mutations. To analyze the changes that second-generation tyrosine kinase inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken of the results of all the BCR-ABL KD mutation analyses performed in the authors' laboratory from January 2004 to January 2013.

Lingua originale	English
pagine (da-a)	N/A-N/A
Rivista	Cancer
Volume	2013
DOI	https://doi.org/10.1002/cncr.28522
Stato di pubblicazione	Pubblicato - 2013

Keywords

BCR-ABL mutations
acute lymphoblastic leukemia
dasatinib
imatinib
resistance

Accesso al documento

10.1002/cncr.28522

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint

Entra nei temi di ricerca di 'Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement'. Insieme formano una fingerprint unica.

Cita questo

Soverini, S., De Benedittis, C., Papayannidis, C., Paolini, S., Venturi, C., Iacobucci, I., Luppi, M., Bresciani, P., Salvucci, M., Russo, D., Sica, S., Orlandi, E., Intermesoli, T., Gozzini, A., Bonifacio, M., Rigolin, G. M., Pane, F., Baccarani, M., Cavo, M., & Martinelli, G. (2013). Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer, 2013, N/A-N/A. https://doi.org/10.1002/cncr.28522

Soverini, Simona ; De Benedittis, Caterina ; Papayannidis, Cristina et al. / Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. In: Cancer. 2013 ; Vol. 2013. pagg. N/A-N/A.

@article{7cbd1e87ac504c559ab5acccfb1f5068,

title = "Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement",

abstract = "Patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib with acquisition of BCR-ABL kinase domain (KD) mutations. To analyze the changes that second-generation tyrosine kinase inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken of the results of all the BCR-ABL KD mutation analyses performed in the authors' laboratory from January 2004 to January 2013.",

keywords = "BCR-ABL mutations, acute lymphoblastic leukemia, dasatinib, imatinib, resistance, BCR-ABL mutations, acute lymphoblastic leukemia, dasatinib, imatinib, resistance",

author = "Simona Soverini and {De Benedittis}, Caterina and Cristina Papayannidis and Stefania Paolini and Claudia Venturi and Ilaria Iacobucci and Mario Luppi and Paola Bresciani and Marzia Salvucci and Domenico Russo and Simona Sica and Ester Orlandi and Tamara Intermesoli and Antonella Gozzini and Massimiliano Bonifacio and Rigolin, {Gian Matteo} and Fabrizio Pane and Michele Baccarani and Michele Cavo and Giovanni Martinelli",

year = "2013",

doi = "10.1002/cncr.28522",

language = "English",

volume = "2013",

pages = "N/A--N/A",

journal = "Cancer",

issn = "0008-543X",

publisher = "River Street:Hoboken, NJ John Wiley & Sons Incorporated",

}

Soverini, S, De Benedittis, C, Papayannidis, C, Paolini, S, Venturi, C, Iacobucci, I, Luppi, M, Bresciani, P, Salvucci, M, Russo, D, Sica, S, Orlandi, E, Intermesoli, T, Gozzini, A, Bonifacio, M, Rigolin, GM, Pane, F, Baccarani, M, Cavo, M & Martinelli, G 2013, 'Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement', Cancer, vol. 2013, pagg. N/A-N/A. https://doi.org/10.1002/cncr.28522

Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. / Soverini, Simona; De Benedittis, Caterina; Papayannidis, Cristina et al.

In: Cancer, Vol. 2013, 2013, pag. N/A-N/A.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

AU - Soverini, Simona

AU - De Benedittis, Caterina

AU - Papayannidis, Cristina

AU - Paolini, Stefania

AU - Venturi, Claudia

AU - Iacobucci, Ilaria

AU - Luppi, Mario

AU - Bresciani, Paola

AU - Salvucci, Marzia

AU - Russo, Domenico

AU - Sica, Simona

AU - Orlandi, Ester

AU - Intermesoli, Tamara

AU - Gozzini, Antonella

AU - Bonifacio, Massimiliano

AU - Rigolin, Gian Matteo

AU - Pane, Fabrizio

AU - Baccarani, Michele

AU - Cavo, Michele

AU - Martinelli, Giovanni

PY - 2013

Y1 - 2013

N2 - Patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib with acquisition of BCR-ABL kinase domain (KD) mutations. To analyze the changes that second-generation tyrosine kinase inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken of the results of all the BCR-ABL KD mutation analyses performed in the authors' laboratory from January 2004 to January 2013.

AB - Patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib with acquisition of BCR-ABL kinase domain (KD) mutations. To analyze the changes that second-generation tyrosine kinase inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken of the results of all the BCR-ABL KD mutation analyses performed in the authors' laboratory from January 2004 to January 2013.

KW - BCR-ABL mutations

KW - acute lymphoblastic leukemia

KW - dasatinib

KW - imatinib

KW - resistance

KW - BCR-ABL mutations

KW - acute lymphoblastic leukemia

KW - dasatinib

KW - imatinib

KW - resistance

UR - http://hdl.handle.net/10807/50967

U2 - 10.1002/cncr.28522

DO - 10.1002/cncr.28522

M3 - Article

SN - 0008-543X

VL - 2013

SP - N/A-N/A

JO - Cancer

JF - Cancer

ER -

Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I et al. Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2013;2013:N/A-N/A. doi: 10.1002/cncr.28522